Proton myo-inositol cotransporter (SLC2A13)

SLC2A13, also known as Proton myo-inositol cotransporter (HMIT), is a membrane transporter protein in the major facilitator superfamily encoded by the SLC2A13 gene in humans. It is primarily expressed in the brain, especially in regions such as the hippocampus, hypothalamus, cerebellum, and brainstem. Unlike other class III GLUT family members, SLC2A13 does not transport glucose, but rather mediates proton-coupled import of myo-inositol and related inositol-phosphates into cells. The protein has 12 transmembrane domains and contains intracellular retention signals, restricting it predominantly to intracellular locations, although it has been detected at the plasma membrane in some tissues and cell types. SLC2A13 is implicated in the regulation of amyloid-beta formation and may play roles in neuronal signaling, osmoregulation, and pH homeostasis. Disease associations include neurodegenerative conditions such as Parkinson’s disease, and research suggests emerging roles as a biomarker in certain cancers[1][3][5][6][8].

Other names

H(+)-myo-inositol symporterH(+)-myo-inositol cotransporterHMITProton myo-inositol cotransporterSolute carrier family 2 member 13Hmit

For researched inhibitors, competitive or non-competitive inhibition of transporter function (GLUT inhibitors block myo-inositol/proton symport)